Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
Anti-CD155/PVR (Extracellular region) Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, IHC |
|---|---|
| Primary Accession | P15151 |
| Host | Mouse |
| Clonality | Mouse Monoclonal |
| Isotype | IgG1 |
| Clone Names | M048 |
| Calculated MW | 45303 Da |
| Gene ID | 5817 |
|---|---|
| Other Names | NECL-5, Nectin-like protein 5, PVR, CD155, Poliovirus receptor |
| Target/Specificity | CD155/Poliovirus receptor (PVR)/nectin-like 5 (Necl-5) is a transmembrane glycoprotein with extracellular immunoglobulin like domains, and an intracellular immunoreceptor tyrosine-based inhibitor motif (ITIM). CD155 was originally described as a mediator of poliovirus attachment to cells, but has also been implicated in adherens junction formation. CD155 binds nectin-3, and interacts with integrin αvβ3 and PDGFR to regulate integrin clustering and focal contact formation at the leading edge of migrating cells. CD155 is also a ligand for immunoreceptors that regulate tumor surveillance. CD155 binds DNAX-associated molecule 1 (DNAX-1), an activating receptor on natural killer cells and cytotoxic T-cells. Alternatively, CD155 may bind TIGIT immunoreceptor inducing an immunosuppressive and non-cytotoxic profile. In cancers, CD155 expression has been associated with unfavorable prognosis in colon cancer, breast cancer, lung adenocarcinoma, pancreatic cancer, melanoma, and glioblastoma. Cancer therapies have targeted CD155 interactions with TIGIT, and have used CD155 as a point of entry for recombinant oncolytic polioviruses. |
| Format | Protein G Purified |
| Storage | Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | Anti-CD155/PVR (Extracellular region) Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
| Shipping | Blue Ice |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
CD155/Poliovirus receptor (PVR)/nectin-like 5 (Necl-5) is a transmembrane glycoprotein with extracellular immunoglobulin like domains, and an intracellular immunoreceptor tyrosine-based inhibitor motif (ITIM). CD155 was originally described as a mediator of poliovirus attachment to cells, but has also been implicated in adherens junction formation. CD155 binds nectin-3, and interacts with integrin αvβ3 and PDGFR to regulate integrin clustering and focal contact formation at the leading edge of migrating cells. CD155 is also a ligand for immunoreceptors that regulate tumor surveillance. CD155 binds DNAX-associated molecule 1 (DNAX-1), an activating receptor on natural killer cells and cytotoxic T-cells. Alternatively, CD155 may bind TIGIT immunoreceptor inducing an immunosuppressive and non-cytotoxic profile. In cancers, CD155 expression has been associated with unfavorable prognosis in colon cancer, breast cancer, lung adenocarcinoma, pancreatic cancer, melanoma, and glioblastoma. Cancer therapies have targeted CD155 interactions with TIGIT, and have used CD155 as a point of entry for recombinant oncolytic polioviruses.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
